Oncotarget editorial board participants William G Kaelin Jr. and Gregg L Semenza purchase 2019 Nobel Prize – EurekAlert

0
3
Oncotarget editorial board participants William G Kaelin Jr. and Gregg L Semenza purchase 2019 Nobel Prize – EurekAlert


The 2019 Nobel Prize in Physiology or Medication has been awarded jointly toOncotargetEditorial Board IndividualsWilliam G. Kaelin Jr. and Gregg L. Semenzafor his or her discoveries of “how cells sense and adapt to oxygen availability”, acknowledged the Nobel Committee. The pair turned into as soon as named alongside the UK doctor-scientist Sir Peter J. Ratcliffe.

The Nobel Committee made the announcement Monday on the Karolinska Institute in Stockholm, Swedenand the discoveries comprise implications for how we perceive and most seemingly address a spread of conditions love most cancers, heart assault, stroke and anemia. The Nobel Laureates identified molecular machinery that regulates the assignment of genes in step with numerous ranges of oxygen.

Gregg L. Semenza is a professor of Medication at Johns Hopkins College and Director of the Vascular Study Program at Johns Hopkins Institute for Cell Engineering. Semenza obtained the Nobel Prize for the discovery of hypoxia-inducible factor 1 (HIF-1), protein, which controls genes in step with adjustments in oxygen availability.

William G. Kaelin Jr., a Professor of medication atHarvard Clinical Collegeand the Dana-Farber Most cancers Institute, earned his portion of the Nobel Prize for his work investigating a genetic syndrome known as Von Hippel-Lindau’s (VHL) illness. Kaelin found that the VHL protein prevents the onset of most cancers and is alive to within the oxygen sensing mechanism thru its interplay with HIF-1.

The awarded mechanism has a elementary importance in physiology, and has a long way-reaching implications for the treatment of lw-oxygen correctly being conditions equivalent to coronary artery illness and tumor explain.

###

Both William G. Kaelin and Gregg L. Semenza are founding participants ofOncotarget, launched in 2010.Oncotargetis a weekly behold-reviewed originate catch admission to bio-scientific journal covering research on all aspects of oncology. The editors-in-chief areMikhail (Misha) BlagosklonnyandAndrei V. Gudkov.

AboutOncotarget

Oncotargetis a weekly, behold-reviewed, originate catch admission to biomedical journal covering research on all aspects of oncology.

Oncotargetis printed by Affect Journals LLC.

To be taught more aboutOncotarget, please lag tohttp://www.ImpactJournals.com

Media Contact:

media@oncotarget.com

800.922.0957

Disclaimer:AAAS and EurekAlert! are now not accountable for the accuracy of data releases posted to EurekAlert! by contributing institutions or for the employ of any data thru the EurekAlert machine.

Be taught Extra

This site uses Akismet to reduce spam. Learn how your comment data is processed.